Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Stereotaxis (STXS) announced the installation of the Genesis Robotic Magnetic Navigation (RMN) systems at Helsinki University Hospital and Banner - University Medicine Heart Institute, the world’s first implementations aimed at treating heart rhythm disorders. These advanced robotic systems enhance precision in cardiac ablation procedures, addressing the growing need for effective solutions for arrhythmias, which can lead to serious health risks. The technology is expected to provide a competitive edge for both institutions in patient care and education in the field.
Stereotaxis (NYSE: STXS) announced that Chairman and CEO David Fischel will speak at RAPS Convergence 2020, the largest annual gathering of healthcare regulatory professionals, on September 13, 2020. Fischel will discuss how regulatory professionals can enhance medical innovation and healthcare access through interoperability and open standards. He emphasized the critical role that regulatory experts play in advancing healthcare innovation. Stereotaxis is known for its robotic technologies that improve arrhythmia treatment. For more information, visit www.stereotaxis.com.
Stereotaxis (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmia treatment, announced CEO David Fischel will present at three investor conferences in September 2020. The presentations include the LD Micro 500 on September 4, Cantor Fitzgerald Global Healthcare on September 15, and Lake Street Best Ideas Growth on September 17, where one-on-one meetings will be available. Fischel aims to share insights on Stereotaxis’ technology and growth strategy, underlining the company’s commitment to enhancing patient care.
Stereotaxis (NYSE: STXS) announced a significant publication in the Journal of the American College of Cardiology, highlighting a study on robotic technology for treating chronic thromboembolic pulmonary hypertension (CTEPH). The trial, involving 50 patients, demonstrated that robotic magnetic navigation enhanced outcomes, with pulmonary vascular resistance improving significantly (p=0.001) and an 86% reduction in heart failure-related hospitalizations (p=0.049) at 12 months. This advancement in robotic technology presents a promising new therapy for pulmonary hypertension, revealing its potential beyond arrhythmias.
Stereotaxis (STXS) reported a 21% decline in second-quarter revenue, totaling $5.3 million, primarily due to a 38% drop in procedure volumes amid COVID-19 challenges. Despite this setback, the company achieved notable milestones, including the installation of the first Genesis RMN® System and advancements in its robotically-navigated ablation catheter. Operating expenses decreased 13% to $6.2 million, demonstrating prudent management. As of June 30, 2020, Stereotaxis held a cash balance of $44 million, positioning it strongly for future growth.
Stereotaxis (NYSE: STXS) and Acutus Medical have successfully conducted the first integrated cardiac ablation procedure utilizing remote TeleRobotic Support. Dr. Gery Tomassoni performed the procedure at Baptist Health in Lexington, KY, combining Stereotaxis Robotic Magnetic Navigation and Acutus' AcQMap systems. This innovative integration enhances the accuracy of arrhythmia treatment through high-resolution imaging and robotic navigation. The TeleRobotic capabilities allow real-time support from experts, improving patient care while minimizing surgical risks.
Stereotaxis (STXS) announced it will release its financial results for Q2 2020 on August 6, 2020, prior to the U.S. market opening. A conference call will follow at 10:00 a.m. ET to discuss the results and corporate developments. Investors can access the call via phone or webcast. Stereotaxis specializes in robotic technologies for treating cardiac arrhythmias, and its systems are approved in several major markets including the U.S., EU, and Japan.
STEREOTAXIS (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmias, announced a publication in the European Heart Journal showcasing its technology's effectiveness in treating a COVID-19 patient with ventricular tachycardia. The publication advocates for remote catheter ablation to reduce infection risks for healthcare staff. The case study involved a 68-year-old patient who recovered without recurrence of arrhythmia. CEO David Fischel emphasized the technology's safety and efficiency in complex procedures, highlighting its role in protecting medical professionals during the COVID-19 pandemic.
Stereotaxis (NYSE: STXS) announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective after the market closes on June 26, 2020. This addition is part of the annual reconstitution of the Russell Indexes, which are relied upon by institutional investors for their integrity. David Fischel, Chairman and CEO, expressed excitement about this milestone, viewing it as a significant step to enhance awareness of the company's innovative cardiac technologies. Stereotaxis specializes in robotic systems for the treatment of arrhythmias and endovascular procedures.
Stereotaxis (NYSE: STXS) announced that Chairman and CEO David Fischel will present at the Cowen 5th Annual FutureHealth Conference on June 25, 2020, at 10:15 am EDT. Fischel will lead a panel titled The Powerful Combination of Advanced Imaging & Robotics, discussing the integration of advanced diagnostic imaging with robotic technologies to enhance patient care. Highlights include Stereotaxis' collaboration with Acutus Medical in cardiac mapping and its efforts in digitizing interventional surgery.